Allopurinol, a frequently used gout medication, does not appear to drive up the risk for dying among gout patients who also struggle with chronic kidney disease, new research shows. The finding is ...

What you need to know ### BMJ Learning To obtain accredited continuous professional development points, subscribers to BMJ Learning can complete the full module at The module contains four additional ...

Allopurinol is currently used as urate-lowering therapy in patients with gout. Findings suggesting that allopurinol-related toxicity is associated with impaired renal function have led to the ...

Improvement observed in estimated glomerular filtration rate in kidney transplant recipients treated with allopurinol for elevated uric acid. Urate-lowering treatment with allopurinol may help ...

In a study of patients hospitalized with acute gout flares and who had prescriptions for allopurinol, those who had their allopurinol dosages decreased had a higher rate of gout flares within 3 months ...

A retrospective comparison of two established gout medications suggested that patients receiving probenecid (Probalan) have a lower cardiovascular risk than peers on the standard therapy of ...

Allopurinol treatment is not associated with increased mortality in patients with gout and chronic kidney disease even at 5 years after starting treatment, a study has found. Around 1 in 5 patients ...

Allopurinol-associated cutaneous adverse reactions severe enough to require hospitalization occurred three to six times as often in Asians, blacks, and Native Hawaiians/Pacific Islanders than in ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. ALLOPURINOL ALPHAPHARM contains the active ingredient allopurinol.

Please provide your email address to receive an email when new articles are posted on . Allopurinol dose escalation for patients with gout did not result in improved survival under the currently ...

Both allopurinol and febuxostat carry similar, significant increased risks for hypersensitivity reactions compared with colchicine, according to data published in Annals of the Rheumatic Diseases.